Recent General Renal Cancer News

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

(December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results... Continue Reading


Lenvima® Approved for Kidney Cancer

(May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received... Continue Reading


Cabometyx® Approved for Kidney Cancer

(May 10, 2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with... Continue Reading


Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

(March 15, 2016)

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an... Continue Reading


FDA Approves Opdivo for Renal Cell Carcinoma

(November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600... Continue Reading


COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

(October 15, 2015)

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared... Continue Reading


Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

(July 29, 2015)

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase... Continue Reading


Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers

(June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading


New Treatment Options for Advanced Renal Cell Carcinoma

(October 8, 2012)

The results from three phase III trials shed new light on treatment options for patients with advanced renal cell carcinoma. The studies were presented at the ESMO 2012 Congress of the European Society... Continue Reading


PD-1 Targeted Immune Therapy Shows Promising Activity

(June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase... Continue Reading


Next Page »